Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05872022
Other study ID # NN9536-4937
Secondary ID U1111-1273-4336
Status Enrolling by invitation
Phase
First received
Last updated
Start date July 5, 2023
Est. completion date December 30, 2032

Study information

Verified date October 2023
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 728
Est. completion date December 30, 2032
Est. primary completion date October 31, 2032
Accepts healthy volunteers
Gender Female
Age group 15 Years to 50 Years
Eligibility Inclusion Criteria: - Signed consent obtained before any study-related activities - Female 15-50 years of age at the time of signing consent - Currently or recently pregnant - Resident of country included in the study - Authorisation for her HCP(s) to provide data to the registry - Exposed to Wegovy cohort: Exposure to at least one dose of Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition. - Unexposed to Wegovy cohort: Have obesity or overweight with at least one weight related comorbid condition at conception Exclusion Criteria: - Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation - Unexposed to Wegovy cohort: Exposure to Wegovy or other GLP-1 RA at any time during pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No Intervention
This is a non-interventional study, therefore no intervention is used.

Locations

Country Name City State
Spain Novo Nordisk Investigational Site Madrid
United Kingdom Novo Nordisk Investigational Site London
United States Novo Nordisk Investigational Site Princeton New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

United States,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Infants with Major Congenital Malformation (MCM) Number of infants with MCM is defined as an abnormality of body structure or function that is present at birth; is of prenatal origin (that is, birth defect); has significant medical, social, or cosmetic consequences for the affected individual; and typically requires medical intervention. From date of conception (DOC) to pregnancy outcome for foetal losses or 12 months of infant age for live births
Secondary Number of Infants with Minor Congenital Malformation Number of infants with minor congenital malformation is defined as an anomaly or abnormality of body structure that is present at birth, is of prenatal origin (that is, birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual. From DOC to pregnancy outcome for foetal losses or 12 months of infant age for live births
Secondary Number of Pregnant Participants With Pre-eclampsia Number of pregnant participants with pre-eclampsia is defined as pregnant participants with high blood pressure and signs of liver or kidney damage occurring at greater than (>) 20 gestational weeks through 6 weeks postpartum. From 20 0/7 gestational weeks to 6 weeks
Secondary Number of Pregnant Participants With Eclampsia Eclampsia is defined as seizures or coma in a woman with pre-eclampsia during pregnancy through 6 weeks postpartum. From 20 0/7 gestational weeks to 6 weeks
Secondary Number of Pregnant Participants Experiencing Spontaneous Abortion Number of pregnant participants experiencing spontaneous abortion is defined as an involuntary foetal loss or the expulsion of the products of conception occurring at less than (<) 20 gestational weeks. From date of conception to 19 6/7 gestational weeks
Secondary Number of Pregnant Participants Experiencing Stillbirth Number of pregnant participants experiencing still birth is defined by the American College of Obstetricians and Gynecologists (ACOG), an involuntary foetal loss occurring at greater than or equal to (>=)20 gestational weeks or, if gestational age is unknown, a foetus weighing >=350 gram. From 20 0/7 gestational weeks to pregnancy outcome (week 40)
Secondary Number of Pregnant Participants With Elective Termination Number of pregnant participants with elective termination is defined as a voluntary foetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or due to foetal abnormalities. From date of conception to pregnancy outcome (week 40)
Secondary Number of Pregnant Participants With Preterm Delivery Preterm birth is defined as a live birth occurring at <37 gestational weeks. From date of conception to 37 gestational weeks (week 37)
Secondary Number of Infants Experiencing Small for Gestational Age (SGA) Birth Number of infants experiencing small for gestational age is defined as weight at birth in <10th percentile for sex and gestational age using standard growth charts for full and preterm live born infants. At delivery of live birth
Secondary Number of Infants With Postnatal Growth Deficiency Number of infants with postnatal growth deficiency is defined as infants with weight, length, or head circumference in <10th percentile for sex and age using standard growth charts. At 4 and 12 months of infant age
Secondary Number of infants with Developmental Delay Infant development delay is defined as infants with failure to achieve the developmental milestones for age, as defined by the Centers for Disease Control and Prevention (CDC). At 4 and 12 months of infant age
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2